These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26585945)

  • 1. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline Variants of Prostate Cancer in Japanese Families.
    Hayano T; Matsui H; Nakaoka H; Ohtake N; Hosomichi K; Suzuki K; Inoue I
    PLoS One; 2016; 11(10):e0164233. PubMed ID: 27701467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
    Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
    PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape of candidate genes in familial prostate cancer.
    Johnson AM; Zuhlke KA; Plotts C; McDonnell SK; Middha S; Riska SM; Schaid DJ; Thibodeau SN; Douglas JA; Cooney KA
    Prostate; 2014 Oct; 74(14):1371-8. PubMed ID: 25111073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 have a limited role in familial prostate cancer.
    Sinclair CS; Berry R; Schaid D; Thibodeau SN; Couch FJ
    Cancer Res; 2000 Mar; 60(5):1371-5. PubMed ID: 10728701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer.
    Marikkannu R; Aravidis C; Rantala J; Picelli S; Adamovic T; Keihas M; Liu T; Kontham V; Nilsson D; Lindblom A
    Anticancer Res; 2015 Jun; 35(6):3155-65. PubMed ID: 26026075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.
    Dębniak T; Scott RJ; Górski B; Masojć B; Kram A; Maleszka R; Cybulski C; Paszkowska-Szczur K; Kashyap A; Murawa D; Malińska K; Kiedrowicz M; Rogoża-Janiszewska E; Rudnicka H; Deptuła J; Domagała P; Kluźniak W; Lener MR; Lubiński J
    PLoS One; 2018; 13(10):e0204768. PubMed ID: 30286154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA mutation in male carriers-ripe for precision oncology?
    Leão RRN; Price AJ; James Hamilton R
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspective: prostate cancer susceptibility genes.
    Simard J; Dumont M; Soucy P; Labrie F
    Endocrinology; 2002 Jun; 143(6):2029-40. PubMed ID: 12021166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of known and novel familial cancer genes in Swedish colorectal cancer families.
    Helgadottir HT; Thutkawkorapin J; Rohlin A; Nordling M; Lagerstedt-Robinson K; Lindblom A
    Int J Cancer; 2021 Aug; 149(3):627-634. PubMed ID: 33729574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.